➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKinsey
Express Scripts
Moodys
Harvard Business School

Last Updated: October 31, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LIFITEGRAST

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Lifitegrast

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00882687 Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis Completed Shire Phase 2 2009-04-01 The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
NCT00926185 A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Completed Shire Phase 2 2009-06-01 The purpose of this study is to evaluate the efficacy of three different concentrations (0.1%, 1.0%, 5.0%) of SAR 1118 Ophthalmic Solution compared to placebo in the treatment of dry eye.
NCT01421498 Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Completed Shire Phase 3 2011-08-01 The purpose of the study is to evaluate the efficacy of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in the treatment of Dry Eye. The safety and tolerability of SAR 1118 Ophthalmic Solution (5.0%) compared to placebo in subjects with dry eye when administered BID for 12 weeks will also be evaluated.
NCT01636206 Safety Study of Lifitegrast to Treat Dry Eye Completed Shire Phase 3 2012-07-01 The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.
NCT01743729 A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye Completed Shire Phase 3 2012-12-01 The purpose of the study is to evaluate the safety and efficacy of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye.
NCT02284516 A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye Completed Shire Phase 3 2014-11-01 Evaluate the efficacy and safety of Lifitegrast in subjects with dry eye disease and a recent history of artificial tear use.
NCT03408015 Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease Not yet recruiting Shire Phase 4 2018-10-01 Every night during sleep, there is an accumulation of white blood cells in the closed eye. The closed eye white blood cells are predominantly neutrophils, but there is a small population (3%) of T cells. The effects of these closed eye white blood cells on dry eye disease pathogenesis have yet to be fully elucidated, but preliminary evidence suggests that closed eye neutrophils may have an associated hyperactivity and increased degranulation in dry eye disease that could contribute to epithelial instability. As an anti-T cell therapy, Xiidra offers an opportunity to better understand how the closed eye white blood cells are recruited and activated. This study also seeks to verify the proposed mechanism of action.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lifitegrast

Condition Name

Condition Name for Lifitegrast
Intervention Trials
Dry Eye 10
Keratoconjunctivitis Sicca 2
Dry Eye Syndromes 2
Contact Lens Complication 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Lifitegrast
Intervention Trials
Keratoconjunctivitis Sicca 12
Dry Eye Syndromes 12
Eye Diseases 6
Keratoconjunctivitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Lifitegrast

Trials by Country

Trials by Country for Lifitegrast
Location Trials
United States 59
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Lifitegrast
Location Trials
Kentucky 4
Massachusetts 4
Tennessee 4
Virginia 3
Missouri 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Lifitegrast

Clinical Trial Phase

Clinical Trial Phase for Lifitegrast
Clinical Trial Phase Trials
Phase 4 7
Phase 3 4
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Lifitegrast
Clinical Trial Phase Trials
Not yet recruiting 7
Completed 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Lifitegrast

Sponsor Name

Sponsor Name for Lifitegrast
Sponsor Trials
Shire 8
University of Alabama at Birmingham 2
Shire Human Genetic Therapies, Inc. 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Lifitegrast
Sponsor Trials
Industry 13
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
AstraZeneca
McKesson
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.